Inside U.S. Trade reports that USTR has begun an “internal review of the controversial pharmaceutical patent proposal that U.S. trade officials tabled” earlier in the TPP negotiations. However, USTR has also signaled new text will not be ready by the next round of negotiations in Singapore in March. The initial U.S. proposal centered around an “access window,” granting TRIPS plus protection to firms that introduced their products within a certain period of time. It was opposed by all of the other negotiators, and the original text was withdrawn.
(See civil society comments on the U.S.’s original proposal here).
In the past Members of Congress have asked the Obama Administration to that text on IPRs uphold the May 10th agreement (a 2007 compromise between the Bush Administration and Congressional Democrats). This would make linkage and patent extensions optional for TPP members, and would limit the duration of data exclusivity.
QUT Media4th November 2025 The United Kingdom Parliament is considering a bill aimed at making smoking obsolete, which has been
Speaking at the Global Expert Network on Copyright User Rights Symposium on 16 June 2025, Professor Christophe Geiger argues for
On 25 September 2025, Professor Wend Wendland, delivered the 14th Peter Jaszi Distinguished Lecture at American University in Washington D.C..
On September 18, 2025, the Italian Senate definitively approved the country’s first comprehensive framework law on artificial intelligence (AI). The
Por Andrés Izquierdo Durante la segunda semana de agosto, fui invitado a hablar en la Feria Internacional del Libro de
By Andrés Izquierdo AI, Copyright, and the Future of Creativity: Notes from the Panama International Book FairDuring the second week